10.5061/DRYAD.TDZ08KPWZ
Hanes, Jozef
0000-0002-3223-8705
AXON Neuroscience (Slovakia)
Kovac, Andrej
AXON Neuroscience (Slovakia)
Kvartsberg, Hlin
AXON Neuroscience (Slovakia)
Kontsekova, Eva
AXON Neuroscience (Slovakia)
Fialova, Lubica
AXON Neuroscience (Slovakia)
Katina, Stanislav
AXON Neuroscience (Slovakia)
Kovacech, Branislav
AXON Neuroscience (Slovakia)
Stevens, Eva
AXON Neuroscience (Slovakia)
Hort, Jakub
Charles University
Vyhnalek, Martin
Charles University
Boonkamp, Lynn
Amsterdam Neuroscience
Novak, Michal
Axon Neuroscience (Cyprus)
Zetterberg, Henrik
University of Gothenburg
Hansson, Oskar
Skåne University Hospital
Scheltens, Philip
Amsterdam Neuroscience
Blennow, Kaj
University of Gothenburg
Teunissen, Charlotte E.
Amsterdam Neuroscience
Zilka, Norbert
AXON Neuroscience (Slovakia)
Novel immunoassay detecting p-Tau Thr217 distinguishes Alzheimer’s Disease
from other dementias
Dryad
dataset
2020
2021-08-11T00:00:00Z
2020-09-30T00:00:00Z
en
https://doi.org/10.1212/WNL.0000000000010814
390878 bytes
4
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Objective To investigate whether p-tau T217 assay in cerebrospinal fluid
(CSF) can distinguishes Alzheimer’s disease from other dementias and
healthy controls. Methods We developed and validated a novel Simoa
immunoassay to detect p-tau T217 in CSF. There was a total of 190
participants from three cohorts with AD (n = 77) and other
neurodegenerative diseases (n = 69) as well as healthy subjects (n = 44).
Results The p-tau T217 assay (cut-off 242 pg/ml) identified AD subjects
with accuracy of 90%, with 78% positive predictive value (PPV), 97%
negative predictive value (NPV), 93% sensitivity, 88% specificity compared
favorably with p-tau T181 ELISA (52 pg/ml) showing 78% accuracy, 58% PPV,
98% NPV, 71% specificity; 97% sensitivity. The assay distinguished AD
patients from age-matched healthy subjects (cut-off 163 pg/ml, sensitivity
98%, specificity 93%) similarly to p-tau T181 ELISA (cut-off 60 pg/ml, 96%
sensitivity and 86% specificity). In AD patients, we found a strong
correlation between p-tau T217-tau and p-tau T181, t-tau and Aβ40 but not
with Aβ42. Conclusions This study demonstrates that p-tau T217 displayed
better diagnostic accuracy than p-tau T181. The data suggests that new
p-tau T217 assay has a potential as an AD diagnostic test in the clinical
evaluation. Classification of Evidence: This study provides Class III
evidence that a CSF immunoassay for p-tau T217 distinguishes AD from other
dementias and healthy controls.